Cassava

SAVA

ATLANTA, GA – – (Globe Newswire – February 5, 2024) – – Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding its business, operations, and compliance policies, including allegations that: (i) the Company failed to maintain adequate and effective data management controls and procedures related to its drug research programs; (ii) as a result, the data published in support of simufilam were susceptible to manipulation to overstate the drug’s effectiveness; (iii) accordingly, Cassava had misrepresented the efficacy of its research programs and the clinical and/or commercial prospects of simufilam; and (iv) all of the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm.

If you bought Cassava shares between August 18, 2022 and October 12, 2023, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/cassava/to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is April 2, 2024.

Registration Deadline

Lead Plaintiff Deadline Has Passed

April 2, 2024

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share